Biomea Fusion, Inc. (BMEA)
NMS · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (18.6M) | (11.7M) | (12.8M) | (12.8M) |
| Net Income | (16.4M) | 4.6M | (12.4M) | (8.3M) |
| Diluted EPS | $-0.27 | N/A | $-0.17 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (83.6M) | (126.1M) | (144.1M) | (81.3M) |
| Net Income | (81.8M) | (117.3M) | (138.4M) | (61.8M) |
| Diluted EPS | $-2.80 | $-3.44 | $-3.83 | N/A |